5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Markers of myocardial injury in the prediction of short-term COVID-19 prognosis Translated title: Marcadores de daño miocárdico en la predicción del pronóstico a corto plazo de los pacientes con COVID-19

      research-article
      a , b , a , b , c , d , e , a , b , e , f , d , e , a , f , a , e , f , e , f , a , a , a , a , a , a , a , e , a , b , c , d , e , , a , b , e , f , , *
      Revista Espanola De Cardiologia (English Ed.)
      Sociedad Española de Cardiología. Published by Elsevier España, S.L.U.
      SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, NT-proBNP, N-terminal pro-B-type natriuretic peptide, hs-cTnT, high-sensitivity cardiac-specific troponin-T, TnT-us, troponina T ultrasensible, NT-proBNP, N-terminal pro-B-type natriuretic peptide, SARS-CoV-2, coronavirus del síndrome respiratorio agudo grave de tipo 2, COVID-19, myocardial injury, Coronavirus, troponin T, NT-proBNP, SARS-CoV-2, COVID-19, Daño miocárdico, Coronavirus, Troponina T, NT-proBNP, SARS-CoV-2

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction and objectives: COVID-19 is currently causing high mortality and morbidity worldwide. Information on cardiac injury is scarce. We aimed to evaluate cardiovascular damage in patients with COVID-19 and determine the correlation of high-sensitivity cardiac-specific troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) with the severity of COVID-19.

          Methods: We included 872 consecutive patients with confirmed COVID-19 from February to April 2020. We tested 651 patients for high-sensitivity troponin T (hs-TnT) and 506 for NT-proBNP on admission. Cardiac injury was defined as hs-TnT  > 14ng/L, the upper 99th percentile. Levels of NT-proBNP  > 300 pg/mL were considered related to some extent of cardiac injury. The primary composite endpoint was 30-day mortality or mechanical ventilation (MV).

          Results: Cardiac injury by hs-TnT was observed in 34.6% of our COVID-19 patients. Mortality or MV were higher in cardiac injury than noncardiac injury patients (39.1% vs 9.1%). Hs-TnT and NT-proBNP levels were independent predictors of death or MV (HR, 2.18; 95%CI, 1.23-3.83 and 1.87 (95%CI, 1.05-3.36), respectively) and of mortality alone (HR, 2.91; 95%CI, 1.211-7.04 and 5.47; 95%CI, 2.10-14.26, respectively). NT-ProBNP significantly improved the troponin model discrimination of mortality or MV (C-index 0.83 to 0.84), and of mortality alone (C-index 0.85 to 0.87).

          Conclusions: Myocardial injury measured at admission was a common finding in patients with COVID-19. It reliably predicted the occurrence of mortality and need of MV, the most severe complications of the disease. NT-proBNP improved the prognostic accuracy of hs-TnT.

          Translated abstract

          Introducción y objetivos: La información sobre el daño miocárdico en la población con COVID-19 es muy escasa. Nuestro objetivo es evaluar el daño cardiaco en pacientes con COVID-19 y determinar la correlación entre las concentraciones de troponina T ultrasensible (TnT-us) y fracción aminoterminal del propéptido natriurético cerebral (NT-proBNP) con la gravedad del COVID-19.

          Métodos: Se incluyó a 872 pacientes consecutivos con COVID-19 confirmada desde febrero a abril de 2020. Se determinó al ingreso la TnT-us a 651 pacientes y la NT-proBNP a 506. El daño miocárdico se definió como una TnT-us > 14 ng/l, > percentil 99. La cifras de NT-proBNP > 300 pg/ml se consideraron relacionadas con daño miocárdico. El objetivo primario es muerte o ventilación mecánica (VM) a 30 días.

          Resultados: Se observó daño miocárdico según la TnT-us en el 34,6%. Las tasas del evento muerte o VM fue superior en los pacientes con daño miocárdico (el 39,1 frente al 9,1%). Los valores de TnT-us y NT-proBNP fueron predictores independientes de muerte o VM (HR = 2,18; IC95%, 1,23-3,83, y HR = 1,87; IC95%, 1,05-3,36), y de mortalidad total (HR = 2,91; IC95%, 1,211-7,04, y HR = 5,47; IC95%, 2,10-14,26). Se observó que la NT-proBNP mejoró de manera significativa el modelo predictivo de la troponina para muerte o VM (estadístico C, 0,83-0,84) y mortalidad total (estadístico C, 0,85-0,87).

          Conclusiones: El daño miocárdico analizado al ingreso se observó con frecuencia entre los pacientes con COVID-19 y es un potente predictor de muerte y necesidad de VM. La NT-proBNP mejoró la precisión pronóstica de la determinación de troponina.

          Related collections

          Author and article information

          Journal
          Rev Esp Cardiol (Engl Ed)
          Rev Esp Cardiol (Engl Ed)
          Revista Espanola De Cardiologia (English Ed.)
          Sociedad Española de Cardiología. Published by Elsevier España, S.L.U.
          1885-5857
          29 September 2020
          29 September 2020
          Affiliations
          [a ]Servicio de Cardiología, Hospital del Mar, Barcelona, Spain
          [b ]Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain
          [c ]Centro de Investigaciones Biomédicas en Red Epidemiología y Salud Pública (CIBERESP), Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain
          [d ]Epidemiología y Genética Cardiovascular, Grupo REGICOR, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain
          [e ]Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain
          [f ]Grupo de Investigación en Enfermedades del Corazón (GREC), Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain
          Author notes
          [* ]Corresponding author: Departamento de Cardiología, Hospital del Mar, Universidad Autónoma de Barcelona, Passeig Marítim 25-29, 08003 Barcelona, Spain
          [◊]

          Dr Marrugat and Dr Vaquerizo contributed equally to this article as senior authors.

          Article
          S1885-5857(20)30414-X
          10.1016/j.rec.2020.09.011
          7522647
          33153955
          47424077-3abf-454a-8298-fad8df8327c8
          © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 29 June 2020
          : 14 September 2020
          Categories
          Article

          sars-cov-2, severe acute respiratory syndrome coronavirus 2,nt-probnp, n-terminal pro-b-type natriuretic peptide,hs-ctnt, high-sensitivity cardiac-specific troponin-t,tnt-us, troponina t ultrasensible,sars-cov-2, coronavirus del síndrome respiratorio agudo grave de tipo 2,covid-19,myocardial injury,coronavirus,troponin t,nt-probnp,sars-cov-2,daño miocárdico,troponina t

          Comments

          Comment on this article